Biomarkers for bladder cancer
The burden of non-muscle invasive bladder cancer (NMIBC) surveillance and the role of biomarkers
-
Watch the editorial comment by Prof. Dr. Paolo Gontero on biomarker statements in the new EAU 2022 guidelines or the surveillance of NMIBC. December 2nd 2022
Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy. Prof. Dr. Gontero is the Chair of the European guidelines for non-muscle-invasive bladder cancer
PlayWatch the editorial comment by Prof. Dr. Paolo Gontero on biomarker statements in the new EAU 2022 guidelines or the surveillance of NMIBC. December 2nd 2022
Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy. Prof. Dr. Gontero is the Chair of the European guidelines for non-muscle-invasive bladder cancer
-
Why urinary biomarkers should be used for the surveillance of non-muscle-invasive bladder cancer. A discussion by an international expert panel at the 19th Meeting of the EAU Section of Oncological Urology (ESOU22), held on 21-23 January 2022 in Madrid, Spain. March 16th, 2022
The implementation and advantages of urinary biomarkers for non-muscle-invasive-bladder (NMIBC) were discussed by an international expert panel at the 19th Meeting of the EAU Section of Oncological Urology (ESOU22), held on 21-23 January 2022 in Madrid, Spain. The panel consisted of Prof. Morgan Rouprêt (Paris, France), Prof. Fred Witjes (Nijmegen, The Netherlands), Dr. Mario Álvarez-Maestro (Madrid, Spain) and Dr. Luis Martínez-Piñeiro (Madrid, Spain).
PlayWhy urinary biomarkers should be used for the surveillance of non-muscle-invasive bladder cancer. A discussion by an international expert panel at the 19th Meeting of the EAU Section of Oncological Urology (ESOU22), held on 21-23 January 2022 in Madrid, Spain. March 16th, 2022
The implementation and advantages of urinary biomarkers for non-muscle-invasive-bladder (NMIBC) were discussed by an international expert panel at the 19th Meeting of the EAU Section of Oncological Urology (ESOU22), held on 21-23 January 2022 in Madrid, Spain. The panel consisted of Prof. Morgan Rouprêt (Paris, France), Prof. Fred Witjes (Nijmegen, The Netherlands), Dr. Mario Álvarez-Maestro (Madrid, Spain) and Dr. Luis Martínez-Piñeiro (Madrid, Spain).
-
The role of biomarkers in the diagnostic process of bladder carcinoma. Watch the presentation of Dr. Félix Guerrero Ramos (Madrid, Spain) October 14th, 2021
The 1st virtual International Workshop in Urothelial Carcinoma took place on the 7th and 14th of October, 2021 and was organized by the university hospital La Paz, IdiPAZ and Grupo Centro de Tumores Genitourinnarios. During the conference, Dr. Felix Guerrero Ramos from University Hospital 12 de Octubre, Madrid gave an interesting presentation on biomarkers in bladder cancer: Watch this presentation to learn more about the limitations of the current follow-up procedures for NMIBC, novel urinary biomarker tests and the clinical application of urinary biomarker tests. Dr. Félix Guerrero Ramos also shares in this presentation his experience in clinical practice with Bladder Epicheck®.
PlayThe role of biomarkers in the diagnostic process of bladder carcinoma. Watch the presentation of Dr. Félix Guerrero Ramos (Madrid, Spain) October 14th, 2021
The 1st virtual International Workshop in Urothelial Carcinoma took place on the 7th and 14th of October, 2021 and was organized by the university hospital La Paz, IdiPAZ and Grupo Centro de Tumores Genitourinnarios. During the conference, Dr. Felix Guerrero Ramos from University Hospital 12 de Octubre, Madrid gave an interesting presentation on biomarkers in bladder cancer: Watch this presentation to learn more about the limitations of the current follow-up procedures for NMIBC, novel urinary biomarker tests and the clinical application of urinary biomarker tests. Dr. Félix Guerrero Ramos also shares in this presentation his experience in clinical practice with Bladder Epicheck®.
-
Urinary biomarkers: Are we prepared to replace cystoscopies? Watch the webinar presentations by Dr. Fernando Lozano and Dr. Alberto Breda June 7th, 2021
On June 7, 2021, HM Hospitales (Spain) organised the webinar “Frequently asked questions in the management of urothelial cancer”. This webinar included 2 presentations addressing the question “Urinary biomarkers: Are we prepared to replace cystoscopies?”: * Urinary biomarkers in bladder cancer, presented by Dr. Fernando Lozano (Vall d’Hebron Barcelona Hospital Campus) * Urinary biomarkers in upper urinary tract urothelial carcinoma (UTUC), presented Dr. Alberto Breda (Fundació Puigvert Barcelona)
PlayUrinary biomarkers: Are we prepared to replace cystoscopies? Watch the webinar presentations by Dr. Fernando Lozano and Dr. Alberto Breda June 7th, 2021
On June 7, 2021, HM Hospitales (Spain) organised the webinar “Frequently asked questions in the management of urothelial cancer”. This webinar included 2 presentations addressing the question “Urinary biomarkers: Are we prepared to replace cystoscopies?”: * Urinary biomarkers in bladder cancer, presented by Dr. Fernando Lozano (Vall d’Hebron Barcelona Hospital Campus) * Urinary biomarkers in upper urinary tract urothelial carcinoma (UTUC), presented Dr. Alberto Breda (Fundació Puigvert Barcelona)
-
Webinar- Epigenetic marker for the monitoring of bladder tumours, Dr. Fernando Lozano Palacio January 26th, 2021
During the virtual VI Symposium Liquid Biopsy, organised from 25 till 27 January 2021 by a scientific committee from the University Hospital of Santiago (Spain), Dr. Fernando Lozano Palacio from the University Hospital Vall d’Hebron (Barcelona, Spain) gave an interesting presentation about biomarkers in bladder cancer, entitled “Epigenetic marker for the monitoring of bladder tumours”.
PlayWebinar- Epigenetic marker for the monitoring of bladder tumours, Dr. Fernando Lozano Palacio January 26th, 2021
During the virtual VI Symposium Liquid Biopsy, organised from 25 till 27 January 2021 by a scientific committee from the University Hospital of Santiago (Spain), Dr. Fernando Lozano Palacio from the University Hospital Vall d’Hebron (Barcelona, Spain) gave an interesting presentation about biomarkers in bladder cancer, entitled “Epigenetic marker for the monitoring of bladder tumours”.
-
Webinar- What is the place of urinary markers in NMIBC follow-up? Prof. Fred Witjes and Dr van der Heijden January 21th, 2021
On Thursday 21 January 2021, MML-Medical, partner of Nucleix in the Netherlands, organised the webinar “Follow-up of NMIBC, including the place of urinary markers”. The webinar included 45 minutes lecture by Prof. Dr. Fred Witjes, Professor of oncological urology, and 15 minutes Q&A, chaired by Dr. Toine van der Heijden, oncological urologist, both from the Radboud UMC Nijmegen, the Netherlands.
PlayWebinar- What is the place of urinary markers in NMIBC follow-up? Prof. Fred Witjes and Dr van der Heijden January 21th, 2021
On Thursday 21 January 2021, MML-Medical, partner of Nucleix in the Netherlands, organised the webinar “Follow-up of NMIBC, including the place of urinary markers”. The webinar included 45 minutes lecture by Prof. Dr. Fred Witjes, Professor of oncological urology, and 15 minutes Q&A, chaired by Dr. Toine van der Heijden, oncological urologist, both from the Radboud UMC Nijmegen, the Netherlands.
-
Editorial comment by Prof. Dr. Paolo Gontero on biomarker statements in the new EAU 2020 guidelines December 14th 2020
Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy. Prof. Gontero is a panel member of the European Guidelines for non-muscle invasive bladder cancer (NMIBC).
PlayEditorial comment by Prof. Dr. Paolo Gontero on biomarker statements in the new EAU 2020 guidelines December 14th 2020
Prof. Dr. Paolo Gontero is Professor of Urology at the University of Turin School of Medicine and Chairmen of the Division of Urology at the San Giovanni Battista (Molinette) Hospital, Italy. Prof. Gontero is a panel member of the European Guidelines for non-muscle invasive bladder cancer (NMIBC).
-
Webinar – Bladder EpiCheck®, for accurate, non-invasive bladder cancer monitoring October 6th 2020
Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands, together with three urologists from Spain (Prof. Dr. Joaquín Carballido, Dr. Marc Serrallach, Dr. Félix Guerrero and Dr. David Parada, pathologist) discussed how the Bladder EpiCheck test is used in their clinical public and private practice.
PlayWebinar – Bladder EpiCheck®, for accurate, non-invasive bladder cancer monitoring October 6th 2020
Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands, together with three urologists from Spain (Prof. Dr. Joaquín Carballido, Dr. Marc Serrallach, Dr. Félix Guerrero and Dr. David Parada, pathologist) discussed how the Bladder EpiCheck test is used in their clinical public and private practice.
-
Webinar Prof. J.A Witjes (Urologist): Follow-up of NMIBC, Including the Place of Urinary MarkersProf. J.A Witjes (Urologist) September 24th 2020
A webinar by Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands and chaired by Dr. Dov Engelstein, Chairman of the Israel Association of Urology (IAU), and Dr. Ran Katz, Associate in the Israel Association of Urology (IAU).
PlayWebinar Prof. J.A Witjes (Urologist): Follow-up of NMIBC, Including the Place of Urinary MarkersProf. J.A Witjes (Urologist) September 24th 2020
A webinar by Prof. Dr. Fred Witjes, Professor of oncological urology at Radboud UMC Nijmegen, the Netherlands and chaired by Dr. Dov Engelstein, Chairman of the Israel Association of Urology (IAU), and Dr. Ran Katz, Associate in the Israel Association of Urology (IAU).
-
Prof. J.A Witjes (Urologist) Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
The burden of non-muscle invasive bladder cancer (NMIBC) surveillance and the role of biomarkers
Play -
Gerard Lensvelt (Patient) Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
The burden of non-muscle invasive bladder cancer (NMIBC) surveillance and the role of biomarkers
Play -
Rob De Vos (Patient) Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
The burden of non-muscle invasive bladder cancer (NMIBC) surveillance and the role of biomarkers
Play
-
EAU21: DNA methylation urine biomarkers test ( Epicheck® assay) in the diagnosis of UTUC. July 11th, 2021 - 1min version
The video shows the results from a single-center prospective study,” evaluated the performance of Bladder EpiCheck in the detection of upper urinary tract urothelial carcinoma (UTUC) among 80 consecutive patients undergoing ureteroscopy for the diagnosis, treatment or follow-up of UTUC.
PlayEAU21: DNA methylation urine biomarkers test ( Epicheck® assay) in the diagnosis of UTUC. July 11th, 2021 - 1min version
The video shows the results from a single-center prospective study,” evaluated the performance of Bladder EpiCheck in the detection of upper urinary tract urothelial carcinoma (UTUC) among 80 consecutive patients undergoing ureteroscopy for the diagnosis, treatment or follow-up of UTUC.
-
EAU21: Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck® in NMIBC surveillance July 11th, 2021 - 4min version
The video shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance.
PlayEAU21: Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck® in NMIBC surveillance July 11th, 2021 - 4min version
The video shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance.
-
EAU21: Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck® in NMIBC surveillance July 11th, 2021 - 1min version
The video shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance.
PlayEAU21: Real world evidence of alternating cystoscopy/cytology with Bladder EpiCheck® in NMIBC surveillance July 11th, 2021 - 1min version
The video shows the results of a pilot performed at Radboud University Medical Center evaluating the feasibility and clinical outcomes of alternating between cystoscopy/cytology and Bladder EpiCheck in non-muscle invasive bladder cancer (NMIBC) surveillance.
Bladder EpiCheck Symposium EAU19
Leading Change in NMIBC Monitoring-Insights from Successful Implementation of Bladder EpiCheck in Clinical Routine
-
Prof. J.A Witjes Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Summary.
Play -
Dr. A. Breda Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
Bladder EpiCheck in upper tract tumors -feasibility study results.
Play -
Prof. R. Miano Università di Roma Tor Vergata, Rome, Italy
Bladder EpiCheck as a tool to reduce re-TURBT – Pilot study results.
Play -
Dr. C. D’Elia Central Hospital of Bolzano, Bolzano, Italy
Adding Bladder EpiCheck to cytology to improve NMIBC detection – experience from a regional public hospital.
Play -
Prof. P. F. Bassi Università Cattolica del Sacro Cuore, Foundation "A. Gemelli" University Hospital, Largo Francesco Vito, Rome, Italy
Utilization of Bladder EpiCheck in high-risk population – experience from a large referral center.
Play -
Prof. S. Lerner Baylor College of Medicine Medical Center, USA
Utilization of cystoscopy, cytology and Bladder EpiCheck – when best to use each one and why?
Play -
Prof. J.A Witjes Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Bladder EpiCheck results - impact on my clinical practice.
Play -
Prof. J.A Witjes Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Introduction.
Play
BLADDER EPICHECK SYMPOSIUM, EAU18
Breaking the Glass Ceiling of Urine Markers in NMIBC Monitoring
-
Prof. R. Miano Università di Roma Tor Vergata, Rome, Italy
Bladder EpiCheck research beyond NMIBC monitoring
Play -
Prof. J.A Witjes Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Introduction / European Multi-Center Study Results / Conclusions
Play -
Prof. S. Shariat Vienna General Hospital, Medical University of Vienna, Vienna, Austria
How does Bladder EpiCheck change my decision making for patients with NMIBC.
Play -
Prof. J.W.F Catto University of Sheffield, Sheffield, UK
Clinical implementation of Bladder EpiCheck in NMIBC monitoring
Play
Subscription Confirmation Required
Go to your email inbox
Go to the inbox of the email
address you just used to sign up.
Open the confirmation email
Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.
Click the confirmation link
Click on the link inside the <br>email and you’re good to go.